Insider Transactions

What Ascendis Pharma A/S's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.

Insider trades

	3 months	12 months
Open-market buys	2	9
Sells	1	2
Total trades	3	11

Shares traded

	3 months	12 months
Acquired	0	0
Disposed	0	0
Net activity	+0	+0

Common stock only — 11 reported trades in the last 12 months are in a security these totals do not cover.

See the story behind these numbers

View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.

Open-market buyer Disclosed 10b5-1 Heavy discretionary Sign up free

All transactions

All Buys Sells

Insider	Relation	Date	Transaction	Shares	Price	Value	Shares held
Holtug Lars	Director	Sep 02	Open-market sale · S	−236	$264.13	−$62.3K	4,000
Bienaime Jean Jacques	Director	Aug 14	Open-market buy · P	+900	$246.91	+$222K	2,900
Bienaime Jean Jacques	Director	Aug 14	Open-market buy · P	+1,100	$245.85	+$270K	2,000
Smith Scott Thomas	EVP & Chief Financial Officer	Jun 02	Open-market buy · P	+100	$219.00	+$21.9K	4,367
Smith Scott Thomas	EVP & Chief Financial Officer	May 29	Open-market buy · P	+250	$223.32	+$55.8K	4,267
Bienaime Jean Jacques	Director	May 29	Open-market buy · P	+100	$223.50	+$22.4K	900
Bienaime Jean Jacques	Director	May 29	Open-market buy · P	+200	$222.30	+$44.5K	800
Bienaime Jean Jacques	Director	May 29	Open-market buy · P	+200	$223.76	+$44.8K	600
Bienaime Jean Jacques	Director	May 26	Open-market buy · P	+200	$239.37	+$47.9K	400
Bienaime Jean Jacques	Director	May 26	Open-market buy · P	+200	$236.24	+$47.2K	200
Jensen Flemming Steen	See Remarks	May 11	Open-market sale · S	−19,460	$238.49	−$4.64M	0

Page 1 of 1 · showing the 11 most recent Sign up free to view all 11 transactions and filter by insider →